An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Carotuximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 10 Oct 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2018.
- 08 Aug 2017 According to a Tracon Pharmaceuticals media release, company expects to report initial data in the first half of 2018.